|
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with nivolumab. |
| |
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD Oncology; Novartis; Otsuka; Pierre Fabre |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Ipsen; Novartis; Pfizer |
Speakers' Bureau - Novartis; Pfizer |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Mundipharma; Pfizer |
Consulting or Advisory Role - Mundipharma |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Travel, Accommodations, Expenses - Sillajen |